<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00474487</url>
  </required_header>
  <id_info>
    <org_study_id>V59P17</org_study_id>
    <nct_id>NCT00474487</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults</brief_title>
  <official_title>A Phase 3, Multi-center Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adults and Compare to the Safety and Immune Response of a Licensed Conjugate Meningococcal ACWY Vaccine in Subjects Aged 19-55 Years of Age and to a Licensed Polysaccharide Vaccine in Subjects Aged 56-65 Years of Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and immune response of Novartis Meningococcal ACWY
      conjugate vaccine in healthy adolescents and adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With at Least One Severe Systemic Reaction, Ages 19 to 55 Years</measure>
    <time_frame>Days 1 to 7</time_frame>
    <description>Safety of the Novartis MenACWY conjugate vaccine and of a licensed meningococcal ACWY conjugate vaccine as measured by the number of subjects presenting at least one severe systemic reaction during the first 7 days following a single vaccination in healthy subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Seroresponse and hSBA ≥ 1:8 (Ages 19 to 55 Years), PP Population</measure>
    <time_frame>1 month postvaccination</time_frame>
    <description>Immunogenicity of the MenACWY vaccine and of a licensed meningococcal ACWY conjugate vaccine, defined as percentage of subjects with seroresponse, human Serum Bactericidal Activity (hSBA) ≥ 1:8 directed against N meningitidis serogroups A, C, W, and Y (healthy subjects aged 19 to 55 years).
Seroresponse: For a subject with hSBA titer &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer ≥ 1:8; for a subject with hSBA titer ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Seroresponse and hSBA ≥ 1:8 (Ages 56 to 65 Years), PP Population</measure>
    <time_frame>1 month postvaccination</time_frame>
    <description>Immunogenicity of the MenACWY vaccine and of a licensed meningococcal ACWY conjugate vaccine, defined as percentage of subjects with seroresponse, human Serum Bactericidal Activity (hSBA) ≥ 1:8 directed against N meningitidis serogroups A, C, W, and Y (healthy subjects aged 56 to 65 years).
Seroresponse: For a subject with hSBA titer &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer ≥ 1:8; for a subject with hSBA titer ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of hSBA GMTs (Ages 19 to 55 Years), PP Population</measure>
    <time_frame>1 month postvaccination</time_frame>
    <description>Immunogenicity of a single dose of MenACWY and of a single dose of the licensed meningococcal ACWY conjugate vaccine, as measured by serum bactericidal activity geometric mean titer (GMT) response using human complement (hSBA GMTs) directed against N meningitidis serogroups A, C, W-135, and Y at 1 month after vaccination, when administered to healthy subjects 19 to 55 years of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of hSBA GMTs (Ages 56 to 65 Years), PP Population</measure>
    <time_frame>1 month postvaccination</time_frame>
    <description>Immunogenicity of a single dose of MenACWY and of a single dose of the licensed meningococcal ACWY conjugate vaccine, as measured by serum bactericidal activity geometric mean titer (GMT) response using human complement (hSBA GMTs) directed against N meningitidis serogroups A, C, W-135, and Y at 1 month after vaccination, when administered to healthy subjects 56 to 65 years of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Local and Systemic Reactions, Ages 19 to 55 Years</measure>
    <time_frame>Days 1 to 7</time_frame>
    <description>Safety profile following a single vaccination of MenACWY CRM vaccine and of a single vaccination of a licensed meningococcal ACWY conjugate vaccine administered to healthy subjects (ages 19 to 55 years).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Local and Systemic Reactions, Ages 56 to 65 Years</measure>
    <time_frame>Days 1 to 7</time_frame>
    <description>Safety profile following a single vaccination of MenACWY vaccine and of a single vaccination of a licensed meninococcal ACWY polysaccharide vaccine administered to healthy subjects (ages 56 to 65 years).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2831</enrollment>
  <condition>Meningococcal Meningitis</condition>
  <condition>Meningococcal Infections</condition>
  <arm_group>
    <arm_group_label>Novartis MenACWY Vaccine (19 to 55 Years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Novartis meningococcal ACWY conjugate vaccine administered to subjects 19 years to 55 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Licensed polysaccharide vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Licensed meningococcal ACWY polysaccharide vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Licensed Conjugate Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Licensed meningococcal ACWY polysaccharide-protein conjugate vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Novartis MenACWY Vaccine (56 to 65 Years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Novartis meningococcal ACWY conjugate vaccine administered to subjects 56 years to 65 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal ACWY Polysaccharide Vaccine</intervention_name>
    <description>One dose of the licensed meningococcal ACWY polysaccharide vaccine was administered by subcutaneous injection.</description>
    <arm_group_label>Licensed polysaccharide vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY CRM (19 to 55 years)</intervention_name>
    <description>One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection to subjects 19 years to 55 years of age.</description>
    <arm_group_label>Novartis MenACWY Vaccine (19 to 55 Years)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal ACWY Conjugate Vaccine</intervention_name>
    <description>One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered by intramuscular injection.</description>
    <arm_group_label>Licensed Conjugate Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Novartis MenACWY Vaccine (56 to 65 Years)</intervention_name>
    <description>One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection administered to subjects 56 years to 65 years of age.</description>
    <arm_group_label>Novartis MenACWY Vaccine (56 to 65 Years)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  individuals who are 19-65 years of age inclusive and who, after the nature of the
             study has been explained have provided written informed consent

          -  individuals who are available for all visits and telephone calls scheduled for the
             study;

          -  individuals who are in good health

        Exclusion Criteria:

          -  individuals with a previous or suspected disease caused by N. meningitidis

          -  individuals with previous immunization with a meningococcal vaccine or vaccine
             containing meningococcal antigen(s)

          -  individuals with previous or suspected disease caused by N. meningitidis

          -  individuals with any serious acute, chronic or progressive disease

          -  individuals who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines and Diagnostics</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Buenos Aires, Argentina</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1406DGI</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cali, Colombia; Bogota, Colombia</name>
      <address>
        <city>Cali; Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Colombia</country>
  </location_countries>
  <results_reference>
    <citation>Stamboulian D, Lopardo G, Lopez P, Cortes-Barbosa C, Valencia A, Bedell L, Karsten A, Dull PM. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America. Int J Infect Dis. 2010 Oct;14(10):e868-75. doi: 10.1016/j.ijid.2010.03.017. Epub 2010 Jul 22.</citation>
    <PMID>20655261</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2007</study_first_submitted>
  <study_first_submitted_qc>May 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2007</study_first_posted>
  <results_first_submitted>March 19, 2010</results_first_submitted>
  <results_first_submitted_qc>July 5, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2010</results_first_posted>
  <disposition_first_submitted>August 3, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>August 3, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 10, 2009</disposition_first_posted>
  <last_update_submitted>April 1, 2014</last_update_submitted>
  <last_update_submitted_qc>April 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal</keyword>
  <keyword>meningitis</keyword>
  <keyword>vaccine</keyword>
  <keyword>adolescents</keyword>
  <keyword>adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Lactitol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled at 3 centers in Argentina and Colombia.</recruitment_details>
      <pre_assignment_details>All subjects enrolled were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Novartis MenACWY Vaccine (19 to 55 Years)</title>
          <description>One dose (0.5 mL of injectable solution) of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly after reconstitution.</description>
        </group>
        <group group_id="P2">
          <title>Novartis MenACWY Vaccine (56 to 65 Years)</title>
          <description>One dose (0.5 mL of injectable solution) of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly after reconstitution.</description>
        </group>
        <group group_id="P3">
          <title>Licensed Conjugate Vaccine (19 to 55 Years)</title>
          <description>One 0.5 mL dose of the licensed meningococcal ACWY conjugate vaccine was administered intramuscularly (Ages 19 to 55 years).</description>
        </group>
        <group group_id="P4">
          <title>Licensed Polysaccharide Vaccine (56 to 65 Years)</title>
          <description>One 0.5 mL dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered subcutaneously(Ages 56 to 65 Years) after reconstitution.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1606"/>
                <participants group_id="P2" count="217"/>
                <participants group_id="P3" count="899"/>
                <participants group_id="P4" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1576"/>
                <participants group_id="P2" count="215"/>
                <participants group_id="P3" count="885"/>
                <participants group_id="P4" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate enrollment</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Novartis MenACWY Vaccine (19 to 55 Years)</title>
          <description>One dose (0.5 mL of injectable solution) of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly after reconstitution.</description>
        </group>
        <group group_id="B2">
          <title>Novartis MenACWY Vaccine (56 to 65 Years)</title>
          <description>One dose (0.5 mL of injectable solution) of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly after reconstitution.</description>
        </group>
        <group group_id="B3">
          <title>Licensed Conjugate Vaccine (19 to 55 Years)</title>
          <description>One 0.5 mL dose of the licensed meningococcal ACWY conjugate vaccine was administered intramuscularly (Ages 19 to 55 years).</description>
        </group>
        <group group_id="B4">
          <title>Licensed Polysaccharide Vaccine (56 to 65 Years)</title>
          <description>One 0.5 mL dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered subcutaneously(Ages 56 to 65 Years) after reconstitution.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1606"/>
            <count group_id="B2" value="217"/>
            <count group_id="B3" value="899"/>
            <count group_id="B4" value="109"/>
            <count group_id="B5" value="2831"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.6" spread="10.1"/>
                    <measurement group_id="B2" value="60.1" spread="2.7"/>
                    <measurement group_id="B3" value="34.8" spread="10.4"/>
                    <measurement group_id="B4" value="60.1" spread="2.6"/>
                    <measurement group_id="B5" value="37.6" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1092"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="627"/>
                    <measurement group_id="B4" value="79"/>
                    <measurement group_id="B5" value="1961"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="514"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="272"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="109"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="249"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="127"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1217"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="658"/>
                    <measurement group_id="B4" value="77"/>
                    <measurement group_id="B5" value="2110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With at Least One Severe Systemic Reaction, Ages 19 to 55 Years</title>
        <description>Safety of the Novartis MenACWY conjugate vaccine and of a licensed meningococcal ACWY conjugate vaccine as measured by the number of subjects presenting at least one severe systemic reaction during the first 7 days following a single vaccination in healthy subjects.</description>
        <time_frame>Days 1 to 7</time_frame>
        <population>The analysis was performed on the safety set. The number of subjects in the safety set is less than the randomized set due to premature withdrawals.</population>
        <group_list>
          <group group_id="O1">
            <title>Novartis MenACWY Vaccine</title>
            <description>One dose of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Licensed Conjugate Vaccine</title>
            <description>One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With at Least One Severe Systemic Reaction, Ages 19 to 55 Years</title>
          <description>Safety of the Novartis MenACWY conjugate vaccine and of a licensed meningococcal ACWY conjugate vaccine as measured by the number of subjects presenting at least one severe systemic reaction during the first 7 days following a single vaccination in healthy subjects.</description>
          <population>The analysis was performed on the safety set. The number of subjects in the safety set is less than the randomized set due to premature withdrawals.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1588"/>
                <count group_id="O2" value="882"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Seroresponse and hSBA ≥ 1:8 (Ages 19 to 55 Years), PP Population</title>
        <description>Immunogenicity of the MenACWY vaccine and of a licensed meningococcal ACWY conjugate vaccine, defined as percentage of subjects with seroresponse, human Serum Bactericidal Activity (hSBA) ≥ 1:8 directed against N meningitidis serogroups A, C, W, and Y (healthy subjects aged 19 to 55 years).
Seroresponse: For a subject with hSBA titer &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer ≥ 1:8; for a subject with hSBA titer ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
        <time_frame>1 month postvaccination</time_frame>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Novartis MenACWY Vaccine</title>
            <description>One dose of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Licensed Conjugate Vaccine</title>
            <description>One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Seroresponse and hSBA ≥ 1:8 (Ages 19 to 55 Years), PP Population</title>
          <description>Immunogenicity of the MenACWY vaccine and of a licensed meningococcal ACWY conjugate vaccine, defined as percentage of subjects with seroresponse, human Serum Bactericidal Activity (hSBA) ≥ 1:8 directed against N meningitidis serogroups A, C, W, and Y (healthy subjects aged 19 to 55 years).
Seroresponse: For a subject with hSBA titer &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer ≥ 1:8; for a subject with hSBA titer ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
          <population>The analysis was performed on the per-protocol (PP) population.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroresponders in serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="71" upper_limit="84"/>
                    <measurement group_id="O2" value="77" lower_limit="71" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroresponders in serogroup C (N= 180, 183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="76" upper_limit="88"/>
                    <measurement group_id="O2" value="81" lower_limit="74" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroresponders in serogroup W (N= 178, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66" lower_limit="58" upper_limit="73"/>
                    <measurement group_id="O2" value="53" lower_limit="46" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroresponders in serogroup Y (N= 181, 182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="74" upper_limit="86"/>
                    <measurement group_id="O2" value="58" lower_limit="51" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:8 in serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="74" upper_limit="86"/>
                    <measurement group_id="O2" value="80" lower_limit="74" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:8 in serogroup C (N= 180, 183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="82" upper_limit="92"/>
                    <measurement group_id="O2" value="92" lower_limit="87" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:8 in serogroup W (N= 178, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="93" lower_limit="89" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:8 in serogroup Y (N= 181, 182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="82" upper_limit="92"/>
                    <measurement group_id="O2" value="76" lower_limit="70" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Seroresponse and hSBA ≥ 1:8 (Ages 56 to 65 Years), PP Population</title>
        <description>Immunogenicity of the MenACWY vaccine and of a licensed meningococcal ACWY conjugate vaccine, defined as percentage of subjects with seroresponse, human Serum Bactericidal Activity (hSBA) ≥ 1:8 directed against N meningitidis serogroups A, C, W, and Y (healthy subjects aged 56 to 65 years).
Seroresponse: For a subject with hSBA titer &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer ≥ 1:8; for a subject with hSBA titer ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
        <time_frame>1 month postvaccination</time_frame>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Novartis MenACWY Vaccine</title>
            <description>One dose of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Licensed Polysaccharide Vaccine</title>
            <description>One dose of the licensed meningococcal ACWY polysaccharide vaccine administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Seroresponse and hSBA ≥ 1:8 (Ages 56 to 65 Years), PP Population</title>
          <description>Immunogenicity of the MenACWY vaccine and of a licensed meningococcal ACWY conjugate vaccine, defined as percentage of subjects with seroresponse, human Serum Bactericidal Activity (hSBA) ≥ 1:8 directed against N meningitidis serogroups A, C, W, and Y (healthy subjects aged 56 to 65 years).
Seroresponse: For a subject with hSBA titer &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer ≥ 1:8; for a subject with hSBA titer ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
          <population>The analysis was performed on the per-protocol (PP) population.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroresponders in serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="76" upper_limit="92"/>
                    <measurement group_id="O2" value="61" lower_limit="45" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroresponders in serogroup C (N= 84, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="74" upper_limit="91"/>
                    <measurement group_id="O2" value="73" lower_limit="57" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroresponders in serogroup W (N= 82, 39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="50" upper_limit="72"/>
                    <measurement group_id="O2" value="54" lower_limit="37" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroresponders in serogroup Y (N= 84, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="67" upper_limit="86"/>
                    <measurement group_id="O2" value="54" lower_limit="37" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:8 in serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="78" upper_limit="93"/>
                    <measurement group_id="O2" value="63" lower_limit="47" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:8 in serogroup C (N= 84, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="82" upper_limit="96"/>
                    <measurement group_id="O2" value="83" lower_limit="68" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:8 in serogroup W (N= 82, 39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="86" upper_limit="98"/>
                    <measurement group_id="O2" value="95" lower_limit="83" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:8 in serogroup Y (N= 84, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="79" upper_limit="94"/>
                    <measurement group_id="O2" value="68" lower_limit="52" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of hSBA GMTs (Ages 19 to 55 Years), PP Population</title>
        <description>Immunogenicity of a single dose of MenACWY and of a single dose of the licensed meningococcal ACWY conjugate vaccine, as measured by serum bactericidal activity geometric mean titer (GMT) response using human complement (hSBA GMTs) directed against N meningitidis serogroups A, C, W-135, and Y at 1 month after vaccination, when administered to healthy subjects 19 to 55 years of age.</description>
        <time_frame>1 month postvaccination</time_frame>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Novartis MenACWY Vaccine</title>
            <description>One dose of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Licensed Conjugate Vaccine</title>
            <description>One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of hSBA GMTs (Ages 19 to 55 Years), PP Population</title>
          <description>Immunogenicity of a single dose of MenACWY and of a single dose of the licensed meningococcal ACWY conjugate vaccine, as measured by serum bactericidal activity geometric mean titer (GMT) response using human complement (hSBA GMTs) directed against N meningitidis serogroups A, C, W-135, and Y at 1 month after vaccination, when administered to healthy subjects 19 to 55 years of age.</description>
          <population>The analysis was performed on the per-protocol (PP) population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="57" upper_limit="105"/>
                    <measurement group_id="O2" value="52" lower_limit="38" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (N=180, 183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" lower_limit="84" upper_limit="153"/>
                    <measurement group_id="O2" value="88" lower_limit="65" upper_limit="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (N=178, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159" lower_limit="123" upper_limit="205"/>
                    <measurement group_id="O2" value="112" lower_limit="87" upper_limit="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (N=181, 182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="70" upper_limit="127"/>
                    <measurement group_id="O2" value="40" lower_limit="30" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of hSBA GMTs (Ages 56 to 65 Years), PP Population</title>
        <description>Immunogenicity of a single dose of MenACWY and of a single dose of the licensed meningococcal ACWY conjugate vaccine, as measured by serum bactericidal activity geometric mean titer (GMT) response using human complement (hSBA GMTs) directed against N meningitidis serogroups A, C, W-135, and Y at 1 month after vaccination, when administered to healthy subjects 56 to 65 years of age.</description>
        <time_frame>1 month postvaccination</time_frame>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Novartis MenACWY Vaccine</title>
            <description>One dose of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Licensed Polysaccharide Vaccine</title>
            <description>One dose of the licensed meningococcal ACWY polysaccharide vaccine administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of hSBA GMTs (Ages 56 to 65 Years), PP Population</title>
          <description>Immunogenicity of a single dose of MenACWY and of a single dose of the licensed meningococcal ACWY conjugate vaccine, as measured by serum bactericidal activity geometric mean titer (GMT) response using human complement (hSBA GMTs) directed against N meningitidis serogroups A, C, W-135, and Y at 1 month after vaccination, when administered to healthy subjects 56 to 65 years of age.</description>
          <population>The analysis was performed on the per-protocol (PP) population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111" lower_limit="70" upper_limit="175"/>
                    <measurement group_id="O2" value="21" lower_limit="11" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (N=84, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196" lower_limit="125" upper_limit="306"/>
                    <measurement group_id="O2" value="86" lower_limit="45" upper_limit="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (N=82, 39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164" lower_limit="112" upper_limit="240"/>
                    <measurement group_id="O2" value="132" lower_limit="76" upper_limit="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (N=84, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121" lower_limit="76" upper_limit="193"/>
                    <measurement group_id="O2" value="28" lower_limit="15" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Local and Systemic Reactions, Ages 19 to 55 Years</title>
        <description>Safety profile following a single vaccination of MenACWY CRM vaccine and of a single vaccination of a licensed meningococcal ACWY conjugate vaccine administered to healthy subjects (ages 19 to 55 years).</description>
        <time_frame>Days 1 to 7</time_frame>
        <population>The analysis was performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Novartis MenACWY Vaccine</title>
            <description>One dose of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Licensed Conjugate Vaccine</title>
            <description>One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Local and Systemic Reactions, Ages 19 to 55 Years</title>
          <description>Safety profile following a single vaccination of MenACWY CRM vaccine and of a single vaccination of a licensed meningococcal ACWY conjugate vaccine administered to healthy subjects (ages 19 to 55 years).</description>
          <population>The analysis was performed on the safety population.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1588"/>
                <count group_id="O2" value="882"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="729"/>
                    <measurement group_id="O2" value="439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="632"/>
                    <measurement group_id="O2" value="392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179"/>
                    <measurement group_id="O2" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="616"/>
                    <measurement group_id="O2" value="375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309"/>
                    <measurement group_id="O2" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197"/>
                    <measurement group_id="O2" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="421"/>
                    <measurement group_id="O2" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ≥38°C (N= 1587, 882)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Other Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280"/>
                    <measurement group_id="O2" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic/Antipyretic Med. Used (N=1588, 881)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250"/>
                    <measurement group_id="O2" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed Home (N= 1585, 880)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Local and Systemic Reactions, Ages 56 to 65 Years</title>
        <description>Safety profile following a single vaccination of MenACWY vaccine and of a single vaccination of a licensed meninococcal ACWY polysaccharide vaccine administered to healthy subjects (ages 56 to 65 years).</description>
        <time_frame>Days 1 to 7</time_frame>
        <population>The analysis was done on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Novartis MenACWY Vaccine</title>
            <description>One dose of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Licensed Polysaccharide Vaccine</title>
            <description>One dose of the licensed meningococcal ACWY polysaccharide vaccine was administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Local and Systemic Reactions, Ages 56 to 65 Years</title>
          <description>Safety profile following a single vaccination of MenACWY vaccine and of a single vaccination of a licensed meninococcal ACWY polysaccharide vaccine administered to healthy subjects (ages 56 to 65 years).</description>
          <population>The analysis was done on the safety population.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ≥38°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any other reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic/Antipyretic Med. Used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed Home (N= 214, 108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were collected from study day 1 to 180.</time_frame>
      <desc>The analysis was performed on the safety set. The number of subjects in the safety set is less than the randomized set due to premature withdrawals.</desc>
      <group_list>
        <group group_id="E1">
          <title>Novartis MenACWY Vaccine (19 to 55 Years)</title>
          <description>One dose of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly.</description>
        </group>
        <group group_id="E2">
          <title>Novartis MenACWY Vaccine (56 to 65 Years)</title>
          <description>One dose of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly.</description>
        </group>
        <group group_id="E3">
          <title>Licensed Conjugate Vaccine (19 to 55 Years)</title>
          <description>One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered intramuscularly in ages 19 to 55 years.</description>
        </group>
        <group group_id="E4">
          <title>Licensed Polysaccharide Vaccine (56 to 65 Years)</title>
          <description>One dose of the licensed meningococcal ACWY polysaccharide vaccine was administered intramuscularly (Ages 56 to 65 Years)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="882"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1588"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="882"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Generalised Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1588"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="882"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1588"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1588"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="882"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1588"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="882"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>HIV Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1588"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="882"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pelvic Inflammatory disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1588"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pyometra</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1588"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1588"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="882"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Arthropod Sting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1588"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Upper Limb Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1588"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1588"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="882"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1588"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1588"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1588"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1588"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="882"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1588"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="882"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Nephrectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1588"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1588"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hypovolaemic Shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1588"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="955" subjects_at_risk="1588"/>
                <counts group_id="E2" subjects_affected="124" subjects_at_risk="216"/>
                <counts group_id="E3" subjects_affected="561" subjects_at_risk="882"/>
                <counts group_id="E4" subjects_affected="62" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="1588"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="216"/>
                <counts group_id="E3" subjects_affected="77" subjects_at_risk="882"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="632" subjects_at_risk="1588"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="216"/>
                <counts group_id="E3" subjects_affected="392" subjects_at_risk="882"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="207" subjects_at_risk="1588"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="216"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="882"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <description>N= 1588, 216, 882, 108</description>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="1588"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="216"/>
                <counts group_id="E3" subjects_affected="115" subjects_at_risk="882"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="1588"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="216"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="882"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="309" subjects_at_risk="1588"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="216"/>
                <counts group_id="E3" subjects_affected="186" subjects_at_risk="882"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="197" subjects_at_risk="1588"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="216"/>
                <counts group_id="E3" subjects_affected="131" subjects_at_risk="882"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="1588"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="216"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="882"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="421" subjects_at_risk="1588"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="216"/>
                <counts group_id="E3" subjects_affected="254" subjects_at_risk="882"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@Novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

